Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(1.00) by 19 percent. This is a 138.24 percent decrease over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $25.752 thousand which missed the analyst consensus estimate of $5.084 million by 99.49 percent. This is a 63.51 percent decrease over sales of $70.570 thousand the same period last year.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.